Comparative Pharmacology
Head-to-head clinical analysis: LOMUSTINE versus TEPYLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMUSTINE versus TEPYLUTE.
LOMUSTINE vs TEPYLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibits DNA synthesis, and produces interstrand crosslinks via chloroethyl carbonium ion formation. Also has carbamoylating activity.
Progestin that transforms endometrium from proliferative to secretory phase, inhibits gonadotropin secretion, and increases cervical mucus viscosity.
130 mg/m² orally as a single dose every 6 weeks; subsequent doses adjusted based on hematologic response.
100 mg orally once daily
None Documented
None Documented
Biphasic: initial half-life ~6 hours; terminal half-life ~16-48 hours (mean 24 hours). Metabolites have prolonged half-life up to 72 hours. Clinical context: accumulation with repeated dosing, requiring 6-week intervals.
Clinical Note
moderateLomustine + Digoxin
"Lomustine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLomustine + Digitoxin
"Lomustine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLomustine + Deslanoside
"Lomustine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLomustine + Acetyldigitoxin
"Lomustine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 10-15 hours in severe renal impairment.
Renal excretion approximately 50% (as metabolites), biliary/fecal excretion approximately 20%; remainder unaccounted, likely metabolized.
Primarily renal (70-80% unchanged) and fecal (15-20% as metabolites).
Category D/X
Category C
Alkylating Agent
Alkylating Agent